首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents.
【24h】

Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents.

机译:作为新型非核苷类抗乙型肝炎病毒药物的6-氯-4-(2-氯苯基)-3-(2-羟乙基)喹啉-2(1H)-一衍生物的构效关系研究。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of novel 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives were synthesized and evaluated for anti-hepatitis B virus (anti-HBV) activities in vitro to explore their structure-activity relationships (SARs). Most of the synthesized compounds possessed potent anti-HBV activity, of which the promising compound 44 exhibited significantly inhibitory potency against the secretion of hepatitis surface antigen (HBsAg) (IC(50) = 0.010 mM, SI > 135), hepatitis e antigen (HBeAg) (IC(50) = 0.026 mM, SI > 51) and the replication of HBV DNA (IC(50) = 0.045 mM). Preliminary mechanism study suggested compound 44 could mainly enhance the transcript activity of HBV ENI (enhancer I), EN-II (enhancer II).
机译:合成了一系列新型的6-氯-4-(2-氯苯基)-3-(2-羟乙基)喹啉-2(1H)-衍生物,并评估了其抗乙型肝炎病毒的体外活性。探索它们的构效关系(SAR)。大多数合成的化合物都具有有效的抗HBV活性,其中有希望的化合物44对肝炎表面抗原(HBsAg)(IC(50)= 0.010 mM,SI> 135),戊型肝炎抗原( HBeAg)(IC(50)= 0.026 mM,SI> 51)和HBV DNA复制(IC(50)= 0.045 mM)。初步机理研究表明,化合物44可以主要增强HBV ENI(增强子I),EN-II(增强子II)的转录活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号